相关实验视频
Updated: May 6, 2026

09:11
Genome Editing with CompoZr Custom Zinc Finger Nucleases ZFNs
Published on: June 14, 2012
25.5K
粘性业务:通过分子来合理化CRBN的指准
Jonathan W Bushman1, Patrick Ryan Potts1
1Induced Proximity Platform, Amgen Research, Thousand Oaks, CA, USA.
Molecular cell
|August 22, 2025
概括
研究人员发现有指的人类蛋白质可以被CRBN向分子合剂降解. 这项研究完善了针对这些具有挑战性的蛋白质的规则, 扩大了治疗选择.
科学领域:
- 生物化学
- 分子生物学
- 药物发现
背景情况:
- Cereblon (CRBN) E3 泛素连接酶复合体是分子合物的关键标.
- 指蛋白 (ZFP) 是人类蛋白质的一大类,其中许多蛋白质由于其结构性质而被认为是"难以使用的药物".
- 了解哪些ZFP易受CRBN介导的降解对于开发新疗法至关重要.
研究的目的:
- 进行人类指蛋白质的综合调查.
- 通过CRBN向分子合剂有效降解的ZFP.
- 完善和扩展现有的规则,规范分子合剂对ZFP的定位.
主要方法:
- 使用基于CRBN的分子粘剂对人类ZFP进行高通量选.
- 蛋白质分析以量化蛋白质降解.
- 生物信息分析以确定降解的序列和结构决定因素.
主要成果:
- 鉴定易受CRBN介导降解的人类ZFP的子集.
- 通过分子来细化与ZFP降解相关的序列和结构图案.
- 扩大已知的ZFP目标以基于CRBN的治疗策略.
结论:
- 针对CRBN的分子可以有效降解特定的人类指蛋白.
- 这项研究为设计针对ZFP的分子提供了精细的指导方针.
- 这些发现推动了以前无法治疗的治疗方法的开发.
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
1.5K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.5K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
780
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
780
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
897
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
897
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
1.1K
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
1.1K
Inflammatory Bowel Disease IV: Pharmacological Management
1.1K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
1.1K
Inflammatory Bowel Disease III: Crohn's Disease
69
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
69

